A trial protocol for the effectiveness of digital interventions for preventing depression in adolescents : The Future Proofing Study by Werner-Seidler, Aliza et al.
STUDY PROTOCOL Open Access
A trial protocol for the effectiveness of
digital interventions for preventing
depression in adolescents: The Future
Proofing Study
Aliza Werner-Seidler1*† , Kit Huckvale1†, Mark E. Larsen1, Alison L. Calear2, Kate Maston1, Lara Johnston1,
Michelle Torok1, Bridianne O’Dea1, Philip J. Batterham2, Susanne Schweizer3,4, S. Rachel Skinner5,
Katharine Steinbeck5, Julie Ratcliffe6, Ju-Lee Oei7, George Patton8, Iana Wong1, Joanne Beames1,
Quincy J. J. Wong9, Raghu Lingam10, Katherine Boydell1, Allison M. Salmon1, Nicole Cockayne1,
Andrew Mackinnon1 and Helen Christensen1
Abstract
Background: Depression frequently first emerges during adolescence, and one in five young people will
experience an episode of depression by the age of 18 years. Despite advances in treatment, there has been limited
progress in addressing the burden at a population level. Accordingly, there has been growing interest in prevention
approaches as an additional pathway to address depression. Depression can be prevented using evidence-based
psychological programmes. However, barriers to implementing and accessing these programmes remain, typically
reflecting a requirement for delivery by clinical experts and high associated delivery costs. Digital technologies,
specifically smartphones, are now considered a key strategy to overcome the barriers inhibiting access to mental
health programmes. The Future Proofing Study is a large-scale school-based trial investigating whether cognitive
behaviour therapies (CBT) delivered by smartphone application can prevent depression.
Methods: A randomised controlled trial targeting up to 10,000 Year 8 Australian secondary school students will be
conducted. In Stage I, schools will be randomised at the cluster level either to receive the CBT intervention app
(SPARX) or to a non-active control group comparator. The primary outcome will be symptoms of depression, and
secondary outcomes include psychological distress, anxiety and insomnia. At the 12-month follow-up, participants in
the intervention arm with elevated depressive symptoms will participate in an individual-level randomised controlled
trial (Stage II) and be randomised to receive a second CBT app which targets sleep difficulties (Sleep Ninja) or a control
condition. Assessments will occur post intervention (both trial stages) and at 6, 12, 24, 36, 48 and 60 months post
baseline. Primary analyses will use an intention-to-treat approach and compare changes in symptoms from baseline to
follow-up relative to the control group using mixed-effect models.
Discussion: This is the first trial testing the effectiveness of smartphone apps delivered to school students to prevent
depression at scale. Results from this trial will provide much-needed insight into the feasibility of this approach. They
stand to inform policy and commission decisions concerning if and how such programmes should be deployed in
school-based settings in Australia and beyond.
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Background
According to the World Health Organization, depression
is the leading cause of disability worldwide [1]. For many
individuals, depression first emerges during adolescence
[2], between age 10 and 24 years [3]. Approximately one
in five young people will experience a depressive episode
by the age of 18 years [4], with earlier onset being associ-
ated with a range of adverse consequences including
poor academic performance, low levels of school attend-
ance, social dysfunction, substance abuse, anxiety, sui-
cidality, poor sleep, diabetes and metabolic syndrome
[5–7]. As adolescents develop, the foundations are laid
for successful transition into the varied roles of adult-
hood including the time in life when employment prod-
uctivity peaks. Experiencing depression as a young
person can negatively impact psychological, social, emo-
tional, educational and vocational pathways into adult-
hood, with profound implications for the individual,
their families and their communities, as well as the
economy [5, 8]. The global cost of mental illness is
nearly US$2.5 trillion, two-thirds of which is incurred
via indirect costs such as unemployment. This cost is ex-
pected to increase to US$6000,000,000,000 by 2030 [9,
10]. By way of benchmarking, total global health expend-
iture in 2009 was US$5.1 trillion, of which less than 2%
is spent on mental health [11]. The immense cost of
mental illness, together with the social and emotional
consequences associated with earlier onset, highlights
the crucial importance of prevention or intervention
early in the course of illness, and, consequently, at an
early age.
There has been little progress in recent years address-
ing this challenge. Estimates suggest that only 13% of
the disease burden due to depression can be alleviated
through current treatments and service models [12].
Even with optimal clinician competence, improved ac-
cess and treatment adherence, only 36% of the burden is
avoidable, leaving substantial unaddressed morbidity and
disability [12]. Currently, fewer than one-third of young
people seek help and gain access to first-line interven-
tions for reasons that include accessibility, stigma and af-
fordability [13]. Of those who seek professional help,
between 30 and 50% of young people do not respond to
treatment [14], and among those who do, over 45% will
experience a subsequent depressive episode [15]. This
has led to growing recognition that treatment alone will
not successfully reduce the burden of depression at a
population level [16].
Prevention represents a separate pathway through
which the burden of depression may be addressed. There
has been bourgeoning interest in the use of preventive
approaches, with several high-quality but small-scale
prevention studies demonstrating that the prevention of
depression is possible in school-aged young people. Sev-
eral recent meta-analyses have examined the effect of
psychological prevention programmes specifically on ad-
olescents and found consistent but small effect sizes in
favour of delivering CBT for depression, at least in the
short term [17–19]. Of the prevention programmes that
are available, those based on cognitive behaviour therapy
(CBT) have been the most frequently evaluated interven-
tions, with evidence to support these approaches [20].
Other approaches may prove effective but have not yet
been subject to rigorous empirical evaluation. CBT in-
volves challenging unhelpful thoughts or beliefs, by gath-
ering evidence which contradict these thoughts or
beliefs from real-world situations. This leads to changes
in emotion and behaviour. CBT is structured, brief and
time-limited, and aims to help individuals develop skills
and strategies to manage their own mood and depres-
sion. Prevention approaches can be delivered either uni-
versally to all individuals within an identified population
regardless of risk (universal prevention), or targeted to
those with risk factors such as low socio-economic back-
ground (selective prevention) or to those who have sub-
threshold disorder symptoms (indicated prevention).
While there is evidence for all three prevention ap-
proaches [18, 19, 21], there have typically been larger ef-
fects reported for targeted approaches, at least in part
due to limitations in the statistical power of universal
prevention studies [22].
Despite consistent statistically and clinically mean-
ingful effects in existing prevention studies, these
studies have been limited by several factors. First, tri-
als have generally involved small sample sizes, and
the consequent limited statistical power means that
potential effects go undetected and/or are measured
imprecisely. Specifically, the median sample size iden-
tified in a recent meta-analysis of 47 studies examin-
ing the prevention of depression was 208, with an
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average effect size of g = 0.23 [19]. Samples of this
size are insufficient because preventive programmes,
particularly universally delivered programmes, neces-
sarily expose a large proportion of individuals not at
risk to the intervention, and yield small to modest ef-
fects because of the low base rates of disorder in gen-
eral population samples [21]. Second, studies have
rarely involved follow-up beyond 12 months, which
limits what is known about long-term preventive ef-
fects. Third, studies have relied solely on self-report
or clinician-reported symptoms. While subjective re-
ports reflect the gold-standard approach and are use-
ful clinically, there is much to be gained by the
inclusion of additional objectively quantifiable data
sources (e.g., health care utilisation data, smartphone-
collected sensor data). Fourth, most prevention ap-
proaches involve the delivery of a single intervention
or programme. There is rarely an option to identify
who is most likely to respond to different interven-
tions, or for a tiered approach whereby individuals for
whom one approach has not been effective may try a
different approach afterwards. This is potentially a
missed opportunity given that not everyone will re-
spond to a single, or the first-line, approach. Finally,
CBT has, until recently, been delivered to young
people generally over 6–12 sessions using face-to-face
approaches which are challenging to scale due to the
expertise and cost required to deliver such pro-
grammes. Digital approaches may be easier to scale
up; however, in a review of 146 randomised con-
trolled prevention trials, only two involved digitally
delivered interventions [18]. In light of these limita-
tions, there is scope to improve on and extend the
empirical base to understand the effects of depression
prevention programmes.
The current study
The Future Proofing Study has been designed to over-
come these challenges by conducting a large school-
based randomised controlled trial (RCT) testing whether
depression can be prevented using a CBT programme
delivered by smartphone application. Research evidence
to date suggests that digital CBT programmes for de-
pression delivered in schools can be effective in reducing
and preventing depression [23]. Partnering in the deliv-
ery of prevention programmes is a natural fit for schools,
which are increasingly seen as settings in which to foster
emotional skill development alongside traditional aca-
demic learning. Mental ill health is associated with
poorer academic performance [24], and depressed young
people miss an average of 22 days of school per year [6],
making mental well-being in line with the goals of edu-
cators and school administrators. Importantly, schools
provide access to large student samples which are more
representative of the general population than other set-
tings, such as mental health services or medical prac-
tices. In addition, the potential to deliver a prevention
programme to all students universally may help reduce
the stigma often associated with the delivery of mental
health interventions only to those with symptoms [13].
This trial will involve up to 10,000 Australian school
students who will be followed up for 5 years. A sample
of this size provides appropriate statistical power to de-
finitively and precisely evaluate effectiveness, as well as
providing the opportunity to conduct robust moderation
and mediation analyses. All study protocols will be deliv-
ered to participants digitally. The intervention/s will be
delivered by smartphone application (apps) and study
surveys can be completed on any Internet-enabled de-
vice (smartphone, tablet, laptop). This delivery method
overcomes the aforementioned challenges associated
with delivery by trained health professionals or teachers.
It is simply too costly to train enough of the workforce
to deliver CBT prevention programmes either individu-
ally or in small groups to make an impact at a popula-
tion level. Delivering interventions digitally is more cost-
effective than face-to-face therapies [25]. Moreover, pro-
grammes using a smartphone app for delivery do not
compromise effectiveness [26]. Testing smartphone apps
represents a major innovation of this project, with most
evaluation of digital programmes focusing on Internet-
based approaches [27]. Digital technologies, and specific-
ally smartphones, are now considered a key strategy to
overcome the barriers inhibiting access to mental health
programmes. This mode of delivery is appropriate given
that young people show a preference for digital tech-
nologies when given the choice, due to the anonymity,
convenience and privacy [12, 28].
This SPIRIT-compliant protocol describes the meth-
odology for a multi-stage, two-arm, parallel group
RCT (Additional file 1). At Stage I, a cluster RCT will
be undertaken to evaluate the effectiveness of SPARX,
which is an app-based CBT gaming intervention [29].
This intervention has been tested in the Australian
adolescent population and was found to be effective
for the prevention of depression [23]. In the current
trial, SPARX will be delivered to Year 8 students (who
are typically aged 12–14 years). The control group will
consist of Year 8 students of an equivalent demo-
graphic who will not receive any intervention. Partici-
pants across both arms will be followed longitudinally
over 5 years. The choice to use a non-active (treat-
ment-as-usual) comparator was made to avoid placing
unnecessary burden on the participants and schools,
which would have been required to provide an
attention-matched placebo intervention—an interven-
tion that would have required an equivalent level of
effort to that of the active condition—that would most
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likely provide no benefit. Other candidate programmes
that may have benefited other outcomes such as life-
style or nutrition programmes could not serve as a fair
control condition because of their likely impact on
mental health. At Stage II (12 months following base-
line), an individual-level RCT will be conducted within
the intervention arm. Individuals who show elevated
symptoms of depression at 12 months will be rando-
mised to an intervention condition that receives a sec-
ond CBT app which targets sleep difficulties (Sleep
Ninja) or a control condition. Sleep Ninja focuses on
sleep disturbances and delivers cognitive behaviour
therapy for insomnia (CBT-I). An intervention target-
ing sleep difficulties was selected because sleep dis-
turbance is both a risk factor and a symptom of
depression, with efficacy supporting its use in the pre-
vention and treatment of depression in both adults
and adolescents [28, 30–32].
Aims
This trial will investigate the impact of two mental
health apps on adolescent depression. The first objective
of this trial is to determine whether delivering a CBT
programme via smartphone application can prevent high
school students in Year 8 from developing depressive
symptoms compared to students in the control arm.
This study will assess the effect of the programme on a
range of secondary outcomes, which include mental
health symptoms (distress, anxiety, insomnia) at post
intervention, 6, 12, 24, 36, 48 and 60months. The effect
of a second intervention on depression in those who
show elevated depressive symptoms 1 year after using
the first SPARX app will also be evaluated. Individual
differences associated with response to the interventions
will also be investigated, including demographics, history
of mental illness, personality factors, social support, so-
cial media use and gender identification, among a range
of other variables (see Table 1). In the control group,
these factors will be examined as possible predictors for
the development of depressive symptoms and other
mental health problems.
The second objective of the trial is to identify the predic-
tors of mental health outcomes from digital behavioural
and cognitive data collected using participants’ smart-
phones (see Table 2 for details). Sensor data will be col-
lected from smartphones to provide information about
activity levels (accelerometery), movement through space
(GPS) and voice patterns to generate a ‘digital phenotype’
for each participant [33–35]. Digital phenotyping can be
understood as using sensor data collected by personal de-
vices to quantify the individual-level human phenotype.
One of the functions of profiling individuals using digital
phenotypes in this way is to make predictions about
changes in mental health. The sensors in smartphones
provide a non-intrusive, minimally burdensome and scal-
able method to investigate the effect of activity and behav-
iour on mental health. Evidence of the validity of this
approach is beginning to emerge, with location variability
now showing an association with depression outcomes in
small studies of adults [36, 37]. However, the use of digital
phenotyping approaches in young people at scale has not
yet been undertaken. For participants in the intervention
group, this information will be combined with intervention
usage data and other study measures to explore predictors
of response and non-response to the intervention apps. In
the control group, this information will be used to pro-
spectively examine predictors of psychopathology.
The third objective of this trial is to evaluate the imple-
mentation of the proposed CBT-based depression preven-
tion programme in the school environment. The data that
will be collected to meet this objective will combine inter-
vention usage with qualitative and quantitative methods.
A protocol for the process evaluation of the programme
implementation will be detailed elsewhere.
Three different forms of data will be collected from this
trial to address each of the objectives: self-report question-
naires (first objective), smartphone-recorded sensor data
and ecological momentary assessment data (second ob-
jective), and usage and implementation data (third object-
ive). This study will also utilise health and education
datasets as a fourth form of data that will be linked to the
main study datasets 1 year after the trial commences, and
then periodically until the trial is complete. Linked data
will include academic outcomes, health service utilisation
and infant development, alongside births and deaths re-
cords. Linkage will allow for a more complete picture of
the education outcomes and the health of the sample and
a cost-effectiveness analysis.
The first form of data (self-report questionnaire data)
will be reported in the primary outcome paper and lim-
ited to primary and secondary outcomes. All other data
types will be reported and published separately.
Hypotheses
The primary hypothesis is that participants allocated to
the intervention arm will show a smaller increase in de-
pressive symptoms relative to those in the control group
at 12 months, measured using the self-report Patient
Health Questionnaire—Adolescent Version (PHQ-A)
[38]. Secondary hypotheses are that depressive symp-
toms will be lower (e.g., show a smaller increase) in the
intervention arm relative to the control arm at other as-
sessment points (post intervention, 6, 24, 36, 48 and 60
months). Using the pre-defined clinical cut-off points on
the PHQ-A will also allow a comparison between likely
cases of depression across the two arms. It is hypothe-
sised that the percentage of depression cases will be
lower in the intervention arm relative to the control arm
Werner-Seidler et al. Trials            (2020) 21:2 Page 4 of 21
Table 1 Summary of primary, secondary and tertiary outcome measures, potential mediating and risk factors, and data collection
time points

















Depression Patient Health Questionnaire: Adolescent
Version (PHQ-A)




Distress Questionnaire 5 (DQ5) ✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Anxiety Spence Children’s Anxiety Scale (SCAS)
including Generalized Anxiety and Social
Phobia subscales
✓ ✓ – ✓ ✓ ✓ ✓ ✓ ✓
Insomnia Insomnia Severity Index (ISI) ✓ ✓ – ✓ ✓ ✓ ✓ ✓ ✓
Tertiary outcome measures, potential mediating variable risk factors
Suicidal ideation Suicidal Ideation Attributes Scale (SIDAS) ✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Suicide
behaviour
Youth Risk Behaviour Survey (YRBS) ✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Externalising
behaviours
Strength and Difficulties Questionnaire
(SDQ)
✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Eating disorders Screen for Disordered Eating (SDE) ✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Self-harm Single question from Self-Harm
Questionnaire
✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Alcohol use Questions from previous National Drug
and Alcohol Research Centre, UNSW
studies
✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Other substance
use
Questions from Australian Institute of
Health and Welfare 2007 National Drug
Strategy Household Survey
✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Psychosis Adolescent Psychotic-like Symptom
Screener (APSS)
✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Sleep quality Pittsburgh Sleep Quality Index (PSQI) ✓ ✓ – ✓ ✓ ✓ ✓ ✓ ✓
Quality of life Child Health Utility 9D (CHU-9D) ✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Well-being Short-form Warwick–Edinburgh Mental
Well-Being Scale (SWEMWBS)
✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Demographics Age, ethnicity, location, language,
perceived socio-economic status
✓ – – – – – – – –
Height and
weight
Height (cm), weight (kg) ✓ – – ✓ – ✓ ✓ ✓ ✓
Personality Big Five Inventory-10 (BFI-10) ✓ – – – – – – – –
School
connectedness
Items from OECD Programme for
International Student Assessment (PISA)
✓ ✓ – ✓ – ✓ ✓ ✓ –
Social support Schuster Social Support Scale (SSSS) ✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Social media use Maladaptive Facebook Use Survey
(MFUS), adapted to apply to social media
use more broadly
✓ ✓ – ✓ – ✓ ✓ ✓ ✓
Gender
identification
Sex at birth and current gender
identification




Single item for each ✓ – – ✓ – ✓ ✓ ✓ ✓
Sexual
behaviour
History of sexual behaviour – – – – – ✓ ✓
Romantic History of romantic relationships ✓ ✓ ✓ ✓ ✓ ✓
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Table 1 Summary of primary, secondary and tertiary outcome measures, potential mediating and risk factors, and data collection
time points (Continued)




























Diagnosed mental health conditions ✓ ✓ – ✓ – – – ✓ ✓




Diagnosed disability ✓ – – – – – – ✓ –
Pubertal
development
Menarche, voice-breaking and Tanner
stages
✓ – – ✓ – ✓ ✓ ✓ ✓
Bullying From previous school trials ✓ ✓ – ✓ – ✓ ✓ ✓ ✓
App feedback/acceptability
App feedback Future Proofing App Feedback Survey – ✓ – – – – – – –
App feedback Post-intervention SPARX-FP Feedback
Survey
– ✓ – – – – – – –
UNSW University of New South Wales
aParticipants selected to take part in Stage II of the trial only








































3 min • • • • • • • • • • • • •
Speed of typing
task
2 min • • • • • • • • • • • • •








3 months of continuous data collection
GPS (location)
device sensor data
3 months of continuous data collection
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at post intervention, 6, 12, 24, 36, 48 and 60 months.
Secondary mental health outcomes are psychological
distress, anxiety and insomnia, and are expected to be
lower in the intervention arm relative to the control, at
post intervention, 12, 24, 36, 48 and 60 months. Add-
itional outcomes including suicidality, substance use and
sleep quality will be reported separately.
For participants in the intervention condition who
show clinically significant depressive symptoms at 12
months (PHQ-A score > 10) and who enter Stage II of
the trial, it is hypothesised that those who receive the
Sleep Ninja intervention will report greater decreases in
symptoms of depression (primary outcome), anxiety and
insomnia (secondary outcomes) from pre to post inter-
vention (Stage II) and from 12 to 24 months (after they
receive the Sleep Ninja intervention), relative to the
Stage II control arm.
Methods
Trial design
This study is a randomised controlled, single-blind trial with
two intervention stages, each consisting of two parallel arms
(intervention and inactive control) with 1:1 allocation at
each stage. Cluster randomisation will occur at the school
level for the first intervention stage, stratified by school size,
school location, school student gender and socio-economic
status (full details in Randomisation section).
The second intervention stage will occur directly after
the 12-month follow-up and involve individual-level ran-
domisation. Stage I of the trial will have eight measure-
ment occasions: baseline (pre-intervention); Stage I post
intervention (immediately after completing the Stage I
intervention, 6 weeks after baseline); and 6-month, 12-
month (primary endpoint), 24-month, 36-month, 48-
month and 60-month follow-up. The follow-up period is
the time since baseline. For the subset of participants in-
volved in Stage II of the trial, an additional measurement
occasion will take place 6 weeks after the Stage II inter-
vention (Stage II post intervention). The trial will take
place in three recruitment waves. It was planned that
Wave 1 will commence in Term 3, 2019 (July 2019),
Wave 2 will commence in Term 2, 2020 (April 2020)
and Wave 3 will commence in Term 3, 2020 (July 2020).
The Stage I intervention phase (SPARX) will last 6 weeks
and have a follow-up period of 5 years. The Stage II
intervention phase (Sleep Ninja) will last 6 weeks, occurs
12 months after Stage I (SPARX) and will have a follow-
up period of up to 4 years.
Data from each assessment point will be used to deter-
mine safety and whether any modifications to the trial
protocol are required (see Analysis section for details). A
concurrent implementation process evaluation will be
conducted, and study processes may be modified to
better address the needs of the school context. Any
change will be reflected in the study protocol and regis-
tration (ACTRN12619000855123).
Setting
This trial will be conducted in approximately 200
schools located predominantly in New South Wales,
Australia. The school system in Australia is divided into
three main school types: government schools, inde-
pendent schools and Catholic schools. Schools from
each of these groups will be recruited into the study.
Schools across metropolitan, regional and rural
locations will be invited to participate in order to gen-
erate a demographically representative sample. Simi-
larly, schools with differing indices of community
socio-educational advantage (ICSEA) will be targeted. If
recruitment targets are not met, schools in Australian
states outside New South Wales will be invited to par-
ticipate. Recruitment is broadly aligned to the academic
calendar, with delivery occurring during Term 2 (April)
and Term 3 (July) such that assessment sessions take
place during the school calendar year and risk issues
can be addressed without delay. The first trial recruit-
ment wave will be conducted primarily in independent
schools in metropolitan Sydney and the Central Coast
for reasons of convenience. The second and third waves
will include both metropolitan and non-metropolitan
sites, and include government, Catholic and independ-
ent schools. Trial management will take place at the
Black Dog Institute, a translational research institute
located in Sydney, Australia that is affiliated with the
University of New South Wales (UNSW).
Participants
As this is a universal prevention study, there are no ex-
clusion criteria. All adolescents enrolled in Year 8 at
each participating school are eligible to participate in the
trial if they have a smartphone with iOS or Android op-
erating system and an active mobile phone number. The
usual age range of students in Year 8 is 12–14 years, al-
though Year 8 students outside this age range will not
be excluded.
Research team roles and responsibilities
Several committees have been established to support the
overall trial governance, each with their own charter and
roles. The most senior committee is the Internal Steer-
ing Committee comprising senior investigators and staff
located at the Black Dog Institute (HC, AW-S, KH, KM,
AMS, NC). This group meets fortnightly and is respon-
sible for guidance and decision-making about the overall
trial design, intellectual contribution to the scientific
quality and strategy, oversight of trial progress and com-
pliance with good clinical practice. The day-to-day trial
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leadership team meets weekly (AW-S, KH, KM) and
leads the operational aspects of the trial, including man-
agement of teams responsible for recruitment and con-
sent (AW-S, KM, LJ) and data management data privacy
and security (KH). A larger Investigator Committee
comprises 20 investigators and collaborators on the pro-
ject who meet annually to provide strategic guidance
and input.
Youth and public involvement
Young people, parents and consumers have been con-
sulted in the preparation phase for the current study.
Recruitment processes and study materials were
reviewed by the Lived Experience Advisory Panel at the
Black Dog Institute, and a local school’s Parents & Citi-
zens (P&C) Association, with changes made based on
suggestions provided. Young people, both through the
Black Dog Institute network and a local mental health
service youth reference group, have been involved in
reviewing all of the questionnaires and informed the
wording of questionnaires and explanation of concepts
using ‘explainers’ to aid clarity. The two interventions
have been subject to youth feedback in previous trials
and iterations of the programmes. For example, young
people who have previously used the SPARX interven-
tion provided acceptability feedback in a previous trial
[23] while Sleep Ninja was developed in collaboration
with young people, and a sample of 50 young people
provided feedback about the intervention in acceptability
surveys and interviews [32].
Recruitment
A flowchart outlining recruitment into the trial, random-
isation at trial Stages I and II, the study timeline and
participation is outlined in Fig. 1. Approximately 200
schools will be recruited to participate in the trial via
several recruitment pathways. The characteristics of the
sample will be compared to school census data to deter-
mine representativeness. Schools will be recruited in
three waves over 2 years: one wave for commencement
of the trial in Term 3, 2019 (12 schools), and then an-
other two waves in Terms 2 and 3, 2020 respectively
(approximately 188 schools).
School principals will be contacted in the first in-
stance. They will be given brief information sheets
containing trial details. Schools will have the oppor-
tunity to hear more information over the telephone
or via video conference. Those who wish to take part
will be instructed to sign and return a letter of sup-
port. Upon receipt of the letter, schools will be ac-
cepted into the trial. In some instances, schools may
approach the Black Dog Institute by submitting an
expression of interest via a link on the study website
(www.futureproofing.org.au) or by directly contacting
staff at the Black Dog Institute.
After schools have consented, parents and students
will be informed about the trial by their school via email
or newsletter, depending on school preferences. A study
invitation will be circulated to parents. This will include
a link to an electronic information sheet and consent
form. Here, parents and students can read information
about the study, download a PDF copy of the study in-
formation sheet and provide electronic consent. Four-
teen days following consent form distribution, schools
with capacity will make follow-up telephone calls to par-
ents who have not submitted a response. The option to
provide verbal consent will be given to these parents.
Students whose parents have consented to their partici-
pation will be given the opportunity to provide consent
electronically at the start of the first study session. On
the consent form, participants indicate whether they
consent to different components of the study, including
the sensor data collection and the linkage component,
and whether they provide permission for their data to be
included in a data repository for use by other re-
searchers. Consent forms are available from the study
website (www.futureproofing.org.au). No biological spec-
imens will be collected. Students who do not provide ac-
tive consent cannot participate in the trial. If a
participant withdraws from the study, they are asked to
indicate whether they give permission for their already
provided data to be used by the study team. All recruit-
ment strategies have ethical approval.
The Black Dog Institute has existing relationships with
100 schools in New South Wales, both through previous
research studies and via delivery of community mental
health literacy programmes to high school students.
These relationships will be leveraged to support school
recruitment. To maximise school consent rates, potential
schools will be approached at least one school term in
advance of study implementation. This means that
schools can schedule study activities well in advance.
Schools who participate in Wave 1 of the study will also
be eligible to participate in Waves 2 or 3 (as these occur
in the subsequent year and therefore involve a different
cohort). As a universal study, schools will be encouraged
to organise data collection assessment sessions as whole-
of-classroom activities. To maximise parental consent
rates, an information video specifically designed for par-
ents will be made available, and parents have the option
to directly contact the research team for further study
information.
Interventions
This trial will involve two interventions: a universal pre-
vention intervention (Stage I; SPARX) and an indicated
prevention intervention (Stage II; Sleep Ninja) for
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Fig. 1 Study flow
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participants showing elevated depressive symptoms 12
months after receiving the universal intervention. Partic-
ipants can begin or continue with any existing treat-
ments during the study, including antidepressants and
psychotherapy, and may receive additional support from
health professionals if required.
SPARX
SPARX is a gaming intervention that was developed as a
treatment programme for mild–moderate depression
[29]. In its original form as a computerised game, re-
search has shown SPARX to be effective in the treat-
ment of adolescent depression, and equally effective as
treatment as usual, which primarily involved face-to-face
psychotherapy with a mental health professional [29].
This trial will use SPARX-Future Proofing (SPARX-FP;
referred to as SPARX in all other sections of the docu-
ment), which is an adaptation of SPARX, to make it suit-
able for the prevention of depression, for delivery via
mobile phone application. The content is the same, but
instead of a focus on existing symptoms and depression,
terminology has been updated to focus on times when
the participants have felt ‘down or stressed’ and included
skills and strategies reframed to focus on dealing with
problems as they arise. The prevention version of
SPARX has been trialled in an Australian sample of 540
final-year secondary school students. This trial showed
that, relative to a control group, those who used the
programme showed lower symptoms of depression in
the lead up to final school examinations [23]. The move
to a mobile phone application from a web-based
programme was informed by this previous study finding
technological barriers to and participant preferences for
delivery via smartphone.
SPARX consists of seven modules (levels) which cover:
finding hope, being active, dealing with strong emotions,
problem-solving, recognising unhelpful thoughts, chal-
lenging unhelpful thoughts and bringing it all together.
Each module takes approximately 20 min to complete.
Each module is designed to be completed on separate
days, and users are encouraged to do one or two mod-
ules per week. Participants will have 6 weeks to complete
the SPARX programme on their personal smartphones,
in their own time or in class time if schools wish to offer
it. Skills learnt through the SPARX programme include
emotion identification, emotion regulation, behavioural
activation (being active), recognising and challenging un-
helpful thoughts and practical problem-solving. This
intervention is delivered in a game format, where partici-
pants begin by choosing a personalised avatar. The gam-
ing component sees the participant undertaking skill-
building challenges in the context of a fantasy world,
where the aim is to restore balance in a world taken over
by gloomy, negative, automatic thoughts. The gaming
component is supplemented by direct instruction, edu-
cation and activities (or homework) provided by a ‘guide’
avatar, who relates the content of the programme to
users’ real-life experiences.
Sleep Ninja
Sleep Ninja is a smartphone app based on CBT-I, which is
the gold standard, evidence-based treatment for insomnia.
Sleep Ninja was developed in collaboration with young
people, and has been tested for feasibility, acceptability and
preliminary effects on insomnia and depression [32, 39].
The intervention involves psychoeducation, stimulus con-
trol, sleep-focused cognitive therapy, basic sleep hygiene
and behavioural activation.
Sleep Ninja takes the form of a chat-bot. When the
app is open, conversation messages appear on the phone
screen from the Sleep Ninja character (who acts as a
sleep coach). Users interact with the Sleep Ninja by
selecting from pre-determined responses, to which the
Sleep Ninja is programmed to respond. Users progress
through six levels or ‘belts’, starting at a white belt and
working their way through to black belt status by the
end of the programme. To level up to the next belt,
users must complete within a 1-week period: one train-
ing session (which takes approximately 5–10 min); and 3
nights of sleep tracking using a sleep diary within the
app. At the completion of each level, users are provided
with a brief report card and graph summarising their
self-reported sleep over that period. There are additional
optional app features that users can access, which in-
clude a meditation recording, extra sleep information,
quick sleep tips and an easy way to send app information
to parents. If participants agree, the app sends a re-
minder each morning to enter sleep tracking from the
night before, a reminder an hour before bed to begin
winding down in preparation for sleep and a final re-
minder at bedtime for users to go to bed. Participants
will have 6 weeks to complete the Sleep Ninja
programme in their own time on their personal
smartphones.
Strategies to enhance and monitor adherence
To enhance adherence, digital notifications and re-
minders will be sent to participants reminding them to
activate, visit and use the app/s as intended. Schools will
provide class time to complete some of the activities
contained in the apps (minimum of four class sessions),
with the rest set for homework. School staff will provide
verbal reminders and encouragement to students to use
the Future Proofing App and, for intervention arm
schools, the first intervention app (Stage I; SPARX) dur-
ing the intervention implementation period. There will
also be a $20 one-off incentive to cover any connectivity
and data costs, delivered post intervention, to
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participants in both arms, which may serve to improve
adherence. Adherence to the intervention app/s will be
monitored by evaluating usage data that are collected
automatically by the apps while they are active. Usage
data are available at the individual level and consist of
when and how many times users enter the apps, how
long they spend in the app, how many modules they
complete and, for Sleep Ninja only, any sleep tracking
data that are input by the user.
Outcomes
The administration schedule for each of the assess-
ment measures described in the following is presented
in Table 1.
Primary outcome measure
Patient Health Questionnaire—Adolescent Version
The primary outcome measure is depression severity mea-
sured at 12 months post baseline using the Patient Health
Questionnaire for Adolescents (PHQ-A) [38]. PHQ-A de-
pression scores will also be collected at baseline, 6 weeks
post intervention (Stages I and II) and at 6, 24, 36, 48 and
60 months post baseline. The PHQ-A is a validated modi-
fication of the PHQ-9 for adolescents, a nine-item self-
administered depression severity screening and diagnostic
tool based on DSM-IV criteria. The scale assesses the fre-
quency of occurrence of nine depression symptom criteria
during the previous 2 weeks, with items rated on a 4-point
scale ranging from 0 (‘Not at all’) to 3 (‘Nearly every day’).
Total scale scores on the PHQ-A depression scale can
range from 0 to 27, with higher scores reflecting more se-
vere depressive symptoms. The accepted clinical cut-off
points are as follows: a score of 0–4 indicates nil to min-
imal symptoms, 5–9 indicates mild symptoms, 10–14 in-
dicates moderate symptoms, 15–19 indicates moderately
severe symptoms and 20–27 indicates severe symptoms.
The psychometric quality of the PHQ-9 and PHQ-A is
well established [38, 40].
Secondary outcome measures
Secondary outcomes will be monitored for the duration
of the trial at baseline, 6 weeks post intervention (Stages
I and II) and the 12-month, 24-month, 36-month, 48-
month and 60-month follow-up assessments (see Table
1 for the specific measurement occasions corresponding
to each outcome measure). The presence of mental
health symptoms will be determined by established cut-
off points relevant to each scale. Analyses will be com-
parisons of mean scores between the intervention and
control arms at each time point. The following measures
will be used to assess the secondary outcomes.
Distress Questionnaire-5
The Distress Questionnaire-5 (DQ-5) [41] is a five-item
brief screening tool for identifying general psychological
distress. Respondents rate each item on a 5-point scale,
ranging from 1 (‘Never’) to 5 (‘Always’). The total scores
on the scale range from 5 to 25, with higher scores indi-
cating greater psychological distress. The scale has dem-
onstrated optimal to high internal consistency and
convergent validity, and has been found to be more ac-
curate in identifying psychological distress than some
other commonly used screeners [41, 42].
Spence Children’s Anxiety Scale Short-Form (including
Generalized Anxiety and Social Phobia subscales)
The Spence Children’s Anxiety Scale Short-Form (SCAS-
SF) is an eight-item brief measure of anxiety for children
and adolescents, based on the SCAS [43]. The SCAS was
designed to measure the severity of children and adoles-
cents’ anxiety symptoms based broadly on DSM-IV criteria
for anxiety disorders [44]. Respondents rate the degree to
which they experience each symptom on a 4-point fre-
quency scale, ranging from 0 (‘Never’) to 3 (‘Always’). Total
scale scores on the eight-item SCAS-SF can range from 0
to 24, with higher scores reflecting greater anxiety. The
SCAS Social Phobia (six items; total score = 0–18) and
Generalised Anxiety (six items; total score = 0–18) sub-
scales will also be administered in this trial to provide spe-
cific validated measures of these common anxiety disorders
in adolescents. The SCAS has demonstrated high internal
consistency and satisfactory test–retest reliability [43]. The
SCAS has also been reported to show both convergent and
divergent validity [45].
Insomnia Severity Index
The Insomnia Severity Index (ISI) is a psychometrically
sound, seven-item self-report measure of insomnia
symptoms over the previous 2 weeks [46]. Responses are
reported on a Likert scale ranging from 0 (‘Not at all’) to
4 (‘Very’), producing total scores of 0–28. Cut-off scores
are as follows: 0–7 reflects no clinically significant in-
somnia, 8–14 indicates subthreshold insomnia, 15–21
suggests moderate severity insomnia and 22–28 indi-
cates severe insomnia. The ISI was designed for use in
adults but has been widely administered to, and vali-
dated in, adolescent samples [47, 48].
Additional outcome measures, potential mediators and
risk factors
The following additional outcome measures will be ex-
amined and reported separately from the primary and
secondary outcomes. Also included are variables which
may mediate outcomes in the intervention arms. Poten-
tial risk factors for the development and maintenance of
mental health disorders are also included (see Table 1
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for the specific measurement occasions corresponding to
each measure).
Suicidal Ideation Attributes Scale
The Suicidal Ideation Attributes Scale (SIDAS) is a re-
cently developed brief measure of suicidal ideation se-
verity in the past month. Using a general population
sample, it has demonstrated high internal consistency
and good convergent validity [49]. The SIDAS consists
of five questions pertaining to frequency of thoughts,
controllability of thoughts, closeness to attempt, level of
distress associated with the thoughts and impact on daily
functioning. Each item is assessed on a 10-point scale.
Endorsement of item 3 (‘How close the individual has
come to making an attempt in the last month’) will trig-
ger the trial’s risk management procedure (see details
later). A total scale score is calculated by summing item
scores and can range from 0 to 50. Higher scores indi-
cate higher levels of suicidal ideation severity.
Youth Risk Behaviour Survey
The Youth Risk Behaviour Survey (YRBS) was de-
signed to assess health risk behaviours among second-
ary school students. Three items from the YRBS will
be used in the current trial to assess suicide-related
behaviours (thoughts, plans and attempts) in the past
12 months, for which participants indicate a ‘Yes’ or
‘No’ response. Studies have shown that the suicidality
items demonstrate both substantial reliability [50] and
good convergent and divergent validity in a secondary
school sample [51].
Strengths and Difficulties Questionnaire
The Strengths and Difficulties Questionnaire (SDQ) [52]
is a widely used behavioural screening questionnaire for
children and adolescents 4–17 years old. The SDQ con-
sists of 25 items divided between five subscales: Emo-
tional Symptoms, Conduct Problems, Hyperactivity/
Inattention, Peer Relationship Problems and Prosocial
Behaviour. Respondents indicate on a 3-point Likert
scale the extent to which each item applies to them,
using the options 0 (‘Not true’), 1 (‘Somewhat true’) or 2
(‘Certainly true’). Total scale scores on each of the sub-
scales can range from 0 to 10. A higher score is indica-
tive of more problems for all subscales, except for the
prosocial scale, where higher scores correspond to fewer
difficulties in prosocial behaviour. The SDQ has demon-
strated good internal consistency across studies [53, 54].
Screen for Disordered Eating
The Screen for Disordered Eating (SDE) [55] was re-
cently developed to screen for eating disorders. The SDE
comprises five items, to which respondents indicate
whether they experience any disordered eating on a
dichotomous scale (‘Yes’ or ‘No’). An individual is
screened as positive if he/she endorses two or more
items. In the primary care setting, this measure has dem-
onstrated good discriminative accuracy [55].
Self-Harm Questionnaire
The Self-Harm Questionnaire (SHQ) [56] was designed
to improve identification of self-harm in adolescents.
The complete questionnaire consists of three screening
questions enquiring about any past incidents of self-
harming behaviour or thinking, followed by 12 add-
itional questions that are only presented to adolescents
reporting previous self-harm. Among a sample of psychi-
atric service inpatients and outpatients, the SHQ has
demonstrated good concurrent and predictive validity
[56]. To assess self-harm prevalence and frequency in
the current trial, only screening item 3 will be adminis-
tered in order to assess past episodes of self-harm (‘Have
you ever actually harmed yourself on purpose? For ex-
ample, have you ever cut yourself or taken an overdose
and it was not an accident?’). Participants respond to
this item on a 4-point scale of ‘No’, ‘Yes, once’, ‘Yes,
two, three or four times’ and ‘Yes, five or more times’.
This item will allow the assessment of the prevalence of
self-harm and its frequency.
Alcohol Use and Substance Use questionnaires
The Alcohol Use questionnaire included in this trial was
originally adapted from the School Health and Alcohol
Harm Reduction Project [57] and used in the Climate
Schools Projects [58], which are Australian school-based
trials aimed at reducing alcohol and cannabis use. The
questionnaire includes a standard drink diagram and nine
items assessing age of first use, alongside frequency and
quantity of alcohol use. An additional questionnaire asses-
sing Other Substance Use was adapted from the Austra-
lian Institute of Health and Welfare 2007 National Drug
Strategy Household Survey. The questionnaire contains
five items assessing recency of substance use, with a spe-
cific focus on cannabis (additional items on age of first use
and frequency of use), and also assesses tobacco, amphet-
amine, ecstasy, hallucinogens, sedatives and inhalant use.
Adolescent Psychotic-Like Symptom Screener
The Adolescent Psychotic-Like Symptom Screener
(APSS) [59] is a seven-item measure designed to identify
people who are at increased risk of future clinical psych-
otic disorder. In this study, only three items will be ad-
ministered to assess paranoia, auditory and visual
hallucinations. For each question, there are three pos-
sible responses: ‘Yes, definitely’, ‘Maybe’ and ‘No, never’.
Responses are scored 1, 0.5 and 0 respectively. Higher
total scale scores on this measure are indicative of
greater psychotic-like symptoms. In the general
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population, this instrument has demonstrated good sen-
sitivity and specificity in identifying young adolescents
with psychotic-like experiences [59].
Pittsburgh Sleep Quality Index
The Pittsburgh Sleep Quality Index (PSQI) [60] was de-
signed to assess sleep quality and disturbances over a 1-
month interval. The PSQI consists of 19 items, which
are used to compute seven component scores: sleep
quality, sleep latency, sleep duration, habitual sleep effi-
ciency, sleep disturbances, use of sleep medications and
daytime dysfunction. Each item is weighted equally on a
scale that ranges from 0 (no difficulty) to 3 (severe diffi-
culty) scale. The seven component scores are then
summed to yield a global score, ranging from 0 to 21;
higher scores indicate worse sleep quality. The PSQI has
demonstrated acceptable to good internal homogeneity,
test–retest reliability and convergent validity across stud-
ies [60–62].
Child Health Utility 9D
The Child Health Utility 9D (CHU-9D) [63] is a nine-
dimension generic preference-based measure designed
to assess child and adolescent health-related quality of
life and suitable for application in economic evaluation.
Current child/adolescent health-related quality of life is
assessed across the domains of worry, sadness, pain,
tiredness, annoyance, school, sleep, daily routine and
activities. Each dimension is rated on a 5-point re-
sponse scale ranging from ‘no’ to ‘severe impairment’.
Responses are then converted to utilities on the 0–1
dead to full health quality-adjusted life years (QALY)
scale using a preference-weighted scoring algorithm
[64]. Previous validation studies with adolescents from
the community and mental health services have dem-
onstrated that the self-complete instrument has accept-
able internal consistency and convergent validity for
children and adolescents aged 7–17 years [65–67].
Short Warwick–Edinburgh Mental Well-Being Scale
The Short Warwick–Edinburgh Mental Well-Being
Scale (SWEMWBS) [68] is a shortened seven-item ver-
sion of the 14-item Warwick–Edinburgh Mental Well-
Being Scale (WEMWBS), which was developed to assess
mental well-being in the general population. The
SWEMWBS consists of seven statements about thoughts
and feelings over the past 2 weeks. Ratings are made on
a 5-point Likert scale (1 = ‘None of the time’, 2 = ‘Rarely’,
3 = ‘Some of the time’, 4 = ‘Often’, 5 = ‘All of the time’).
Total scale scores are calculated by summing item scores
and transforming the total score using a conversion
table. Total scores can range from 7 to 35. A higher
score indicates a higher level of mental well-being. The
SWEMWBS has demonstrated adequate reliability and
validity across studies [69, 70].
Demographic information
At the baseline assessment, participants will be asked to
provide their date of birth, postcode, country of birth,
language spoken at home, who they live with at home,
Aboriginal and Torres Strait Islander status, and socio-
economic status [71].
Height and weight
Self-reported height (cm) and weight (kg) will be
provided.
Big Five Personality Inventory
The Big Five Personality Inventory (BFI-10) [72] is a 10-
item scale measuring the Big Five personality traits: Extra-
version, Agreeableness, Conscientiousness, Neuroticism
and Openness. The scale was developed based on the 44-
item Big Five Inventory (BFI-44) [73]. Respondents indi-
cate their level of agreement with each described trait on a
5-point scale, ranging from 1 = ‘Disagree strongly’ to
5 = ‘Agree strongly’. Total subscale scores are calculated
by summing item scores (two items per subscale). Sub-
scale scores can range from 2 to 10. The BFI-10 has dem-
onstrated acceptable test–retest reliability and good
construct validity across studies [72, 74].
School connectedness
School connectedness will be assessed using question-
naire items developed by the Organisation for Economic
Co-operation and Development (OECD) Programme for
International Student Assessment [75]. Six items will be
administered, which are rated on a 4-point scale from 1
(‘Strongly agree’) through to 4 (‘Strongly disagree’). Total
scale scores can range from 6 to 24, with higher scores
reflecting greater school connectedness.
Schuster Social Support Scale
The Schuster Social Support Scale (SSSS) [76] is a 15-
item measure of positive and negative interactions with
family, friends and spouse. In the current study, 10 items
will be administered to assess interactions with family
and friends only. Each item is rated on a 4-point scale
ranging from 0 (‘Never’) through to 3 (‘Often’). Scores
are interpreted per category, for friends and family, with
higher scores on the supportive interactions scales indi-
cative of more supportive interactions, and higher scores
on the negative interactions scales indicate more nega-
tive interactions.
Maladaptive Facebook Usage Scale (adapted)
The Maladaptive Facebook Usage Scale [77] is a seven-
item measure of maladaptive Facebook usage, which
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assesses an individual’s tendency to undertake negative
social evaluations and social comparisons when they use
Facebook. This scale has demonstrated good test–retest
reliability and convergent validity [77]. In this trial, the
scale has been adapted to incorporate social media more
broadly. A screening item has been added asking respon-
dents to nominate which social media platforms they
use at least once per week. Options include: Facebook,
Instagram, Snapchat, Tumblr, Twitter, YouTube, Reddit,
Other and ‘I don’t use social media’. The seven items of
the Maladaptive Facebook Usage Scale were adapted to
apply to any social media platform (e.g. ‘I tend to read
the social media status updates of others to see if they
are feeling the way I am’ and ‘Reading the social media
status updates of others tends to make me feel down on
myself’). Items are rated on a response scale from 1
(‘Strongly disagree’) to 7 (‘Strongly agree’). Total scale
scores can range from 7 to 49. Higher scores indicate
greater tendencies to seek online social comparisons and
negative evaluations.
Gender identification and sexual identification/preferences
Gender identification (two items: sex at birth and
current gender identity) and sexual identification and
preferences (one item for each) will be examined at
baseline and annually between 12-month and 60-month
follow-up.
Romantic relationships
Two items will be presented at multiple time points to
assess romantic relationships. These items will ascertain
the number of special or important romantic relation-
ships in the past year, as well as the number of break-
ups in the past 12 months.
Sexual behaviour
A series of questions will be presented at the 24-month
follow-up when participants are in Year 10 (aged 15–16
years) to assess sexual behaviour, taken from the Na-
tional Survey of Australian Secondary Students and Sex-
ual Health [78]. These items will assess experience and
age of first ‘making out’, intimate genital touching and
sex, as well as number of people they have had sex with
during the past year and frequency of condom use. This
section will include an initial gating item assessing his-
tory of intimate sexual contact. Those who do not en-
dorse this item will not receive the other sexual
behaviour items.
Trauma Behavioural Risk Factor Surveillance
System—Adverse Childhood Experience Module
The Trauma Behavioural Risk Factor Surveillance Sys-
tem—Adverse Childhood Experience Module (BRFSS-
ACE) [79] consists of 11 items that assess exposure to
nine types of adverse childhood experiences in the first 18
years of life, including: verbal abuse, physical abuse, sexual
abuse, household mental illness, household alcohol abuse,
household drug abuse, domestic violence, parental separ-
ation/divorce and incarcerated family members. The re-
sponses are dichotomised to indicate exposure and
summed to create an ACE score ranging from 1 to 8 for
each subdomain, with higher scores indicating greater ex-
posure. Previous studies have demonstrated that this in-
strument has adequate internal consistency and validity
[80, 81]. In this trial, the complete BRFSS-ACE will be ad-
ministered at 48-month follow-up when participants are
near 18 years of age. A modified version of the question-
naire consisting of eight items will be administered at
baseline when participants are approximately 13 years old.
This modified scale excludes items on physical and sexual
abuse, and includes additional items assessing out-of-
home or foster care and feelings of endangerment or
physical harm.
History of mental health diagnosis
One item will assess the lifetime history of diagnosed
mental health problems (major depression, social anxiety
disorder, generalised anxiety disorder, obsessive compul-
sive disorder, panic disorder, alcohol use disorder, sub-
stance use disorder, attention deficit hyperactivity
disorder, post-traumatic stress disorder, schizophrenia/
psychosis).
Hospitalisation
One item will assess hospitalisation in the previous 12
months and will ask participants to distinguish between
hospitalisation for physical and mental health problems.
History of disability diagnosis
One item will assess the lifetime history of diagnosed
disability (autism or Asperger’s syndrome, intellectual
disability, specific learning disability, Tourette syndrome,
cerebral palsy, acquired brain injury, other neurological
disability, hearing impairment, visual impairment).
Pubertal development
A separate set of questions for females and males will be
used to assess pubertal development (e.g., ‘at what age
did you get your first period/did your voice begin to
break?’). Participants will also be provided with line
drawings of stages of pubertal development (Tanner
Stages) and asked to rate their current stage of physical
development against these images.
Bullying
Bullying items were drawn from previous school-based
trials. The three items examine whether participants
have been bullied, have been cyber-bullied or have
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bullied others in the past 12 months. Items are
responded to on a 5-point frequency scale from 1 (‘Not
at all’) to 5 (‘Most days’).
App use and feedback surveys
App use and feedback surveys for both the Future Proof-
ing app and the SPARX app will be administered at the
post-assessment time point. The Future Proofing App
Survey was developed for this study and has nine items
which assess app task preferences and reasons for dis-
continued use. The SPARX Feedback Survey is an 11-
item survey that has been used previously to assess
SPARX use [23] and app acceptability, and asks partici-
pants to select any skills they learnt from using the app.
Smartphone-collected data
Additional data will be collected directly via smart-
phones through a study app developed for this study
(the Future Proofing App), as these data cannot be col-
lected from the self-report questionnaires outlined earl-
ier. Three forms of data will be collected, which include
actively collected data, passively collected data and app
usage data. Actively collected data will assess self-
reported mood ratings, voice samples and cognitive
tasks. This form of data will overcome biases in retro-
spective reporting of mood and allow for an investiga-
tion of whether changes in voice are related to changes
in mental health states. Cognitive tasks include two mea-
sures of executive function presented in affective and
neutral contexts. Specifically, a measure of affective
shifting [82] and the Affective Digit Span [83] and a typ-
ing speed task, which will allow for a mechanistic assess-
ment of the way cognitive function affects psychological
outcomes in adolescents.
Passively collected smartphone data will involve the
collection of location data (GPS) and movement data
(accelerometry), which will be used to investigate
whether mental health changes can be predicted from
location and activity data. Smartphone sensor data will
be collected during the first 3 months of the study, and
at each annual assessment point for 3-month periods.
App usage data will allow for assessment of app use and
completion, and time spent using the study app/s.
Linked data
Data relating to participants’ academic outcomes, phys-
ical health, utilisation of health services, infant develop-
ment, births and deaths will be linked from extant
Australian government administrative datasets by an
authorised agency of the New South Wales Ministry of
Health, the Centre for Health Record Linkage (CheReL,
www.cherel.org.au). Informed consent from each partici-
pant will be obtained prior to linkage and databases will
be linked using personal identifiers such as names, dates
of births, addresses and hospital identification numbers
with probabilistic methods. Linked data will be provided
to the researchers in a de-identified manner and will be
used to determine related health and other outcomes for
the participant, including birth and perinatal data, edu-
cational outcomes in standardised curriculum-based
tests, and hospitalisation and mortality outcomes. Link-
age will occur within the first 12–24months of the study
(at the end of 2020) and will be updated periodically
every 2 years until the trial concludes.
Procedure and participant timeline
Figure 1 shows the participant timeline and flow. An ini-
tial preparatory phase and first school visit will solicit
parental and student consent, ensure that electronic
study questionnaires are accessible by consented stu-
dents and ensure that the appropriate study apps are in-
stalled on each student’s device. Each subsequent school
visit will coincide with an assessment occasion. During
these visits, students will access study questionnaires via
a secure online portal, accessible using their mobile
number and a one-time password sent via SMS. Study
personnel will attend these school visits to assist with
technical issues and participants’ questions. Following
completion of baseline questionnaires, participants in
the intervention condition will be instructed to com-
mence the intervention both during class time and in
their own time, and will receive notifications and re-
minders over the following 6 weeks to do so. Schools are
required to schedule four 20-min in-class sessions for
intervention completion but may choose to hold add-
itional sessions (up to seven). Participants in the control
condition will also be provided with equivalent class
time to complete activities on the Future Proofing app.
Students who do not complete assessments in school
will also have the option to do this in their own time.
Students will have up to 4 weeks following the scheduled
assessment date to complete questionnaires at each time
point, after which the assessment surveys will be locked
and no longer accessible. During this 4-week window,
automated electronic reminders will be sent to students
to prompt completion, if required.
Sample size
Separate sample size estimates were derived to deter-
mine the numbers of participants needed to meet the
aims of each trial stage. Power was set at 0.80, α = 0.05
(two-tailed), and a correlation of 0.5 assumed between
baseline and endpoint symptom scores. To account for
possible clustering effects at Stage I (i.e., participants
from the same school having prognostically relevant
characteristics and outcomes more alike than between
schools), a design effect [84] was calculated assuming an
intraclass correlation coefficient (ICC) of 0.03 (based on
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previous school-based studies) [85] and a cluster size of
50 students, yielding a design effect of 2.47. In order to
detect a mean standardized difference of 0.3 between
conditions at Stage I, a sample of 870 participants would
be needed (435 per arm). Allowing for up to 30% attri-
tion, recruitment of 1244 participants would be required
(622 per arm).
Using similar parameters for Stage II (without a design
effect) would require recruitment of 368 participants in
total to detect the same effect size. However, participants
in this stage must meet eligibility requirements regarding
elevated symptoms and failure to respond to the first-
stage intervention. They must also be willing to partici-
pate. Accordingly, a scenario involving recruitment of
10,000 participants at Stage I was considered, assuming
7000 participants would have endpoint data available at
12 months (allowing for 30% attrition). Conservatively
estimating 20% having PHQ-A scores ≥ 10, 25% showing
a reduction due to the Stage I intervention and that 50%
of those eligible to enrol at Stage II do so, 525 partici-
pants would enter this stage II, with endpoint data avail-
able for at least 368 (allowing for up to 30% attrition).
This sample would enable the detection of differences in
changes in symptomatology scores of comparable size to
those in Stage I of the trial (d = 0.29).
Given that a target sample of 10,000 is substantial, if
the numbers of participants are not sufficient to reach
the Stage II target, then supplementing this sample with
additional young people specifically targeted based on
PHQ-A scores that fall in the top 20% of population
scores to ensure that this stage of the trial has compar-
able power to Stage I to detect an intervention effect will
be considered. This will ensure that sufficient numbers
are included at both stages of the trial. Should the target
be met, Stage I of the trial will have much higher power
to detect changes in symptom scores and would be ad-
equately powered to detect differences in incidence
based on PHQ-A diagnosis criteria.
Exploratory analyses for moderating and mediating ef-
fects will be feasible at both stages. Stage II will have
power to detect small to medium mediation effects [86].
Power to detect medium-size effects (0.5 SD) in moder-
ation analyses will be maintained for subgroups down to
approximately 120 participants. Power will be enhanced
in longitudinal modelling (growth curves) which use
multiple occasions of measurement to estimate rates of
change [86].
Randomisation
For Stage I, cluster randomisation (at the school level)
will be employed for administrative convenience, to
avoid control condition contamination, and for the eco-
logical validity of providing the intervention at the clus-
ter level. Schools will be randomised after they are
recruited into the trial. The trial statistician who is not
involved in the day-to-day running of the trial will per-
form the randomisation, and the identity of the school
will be concealed from the statistician.
Schools will be randomised with a 1:1 allocation, as
per a computer-generated randomisation schedule. Bal-
ance between the trial arms will be achieved by stratify-
ing based on school size, school location (metropolitan
vs. regional), school type (co-educational or gender se-
lective) and Index of Community Socio-Educational Ad-
vantage (ICSEA) level. For Stage II, individual-level
randomisation with a 1:1 allocation using a computer-
generated randomisation schedule stratified by gender
and depression severity scores will be employed. This
procedure is automated through the Black Dog Institute
research platform. Permuted block randomisation will
be used at both stages but will not be disclosed to ensure
concealment. Allocation to arms is not directly commu-
nicated to schools. However, because the study has no
control intervention, schools, participants and study op-
erational staff will be aware of school allocation to the
intervention arm. With the exception of the trial data
manager, other individuals not involved in the day-to-
day running of the trial will remain blind to allocation.
All outcome assessments are conducted electronically
and not subject to assessor bias. Unblinding at the con-
clusion of analysis will be performed by the trial data
manager with authorisation from the Trial Steering
Committee.
Participant risk management protocol
An independent Data and Safety Monitoring Committee
(DSMC) has been established to monitor the quality of
trial data and the safety of research participants. The
DSMC will be responsible for safeguarding the interests
of participants through regular monitoring, including
participant safety and adverse events. This group will be
responsible for monitoring the efficacy of the interven-
tions being tested on primary outcomes, as well as the
overall conduct of the study, including recruitment,
protocol compliance, accuracy and completeness of data
collection. This group will also provide recommenda-
tions with respect to continuing, modifying or terminat-
ing the trial, on the basis of feasibility or safety concerns,
and will have access to unblinded data. This group can
recommend the trial team be unblinded if there are ser-
ious safety concerns and meets every 6 months to review
trial conduct. There is no anticipated harm from this
trial, as it involves a population-based sample and
evidence-based interventions. However, should there be
any unanticipated harms, this will be monitored by the
DSMC, who will provide recommendations about care
for affected participants.
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All students involved in the trial will be assessed for
suicidal thinking and behaviour at each assessment
point, using the SIDAS and the YRBS. If participants
indicate serious suicidal thinking, plans or behaviour
on study surveys, an alert will be triggered whereby
the research team and school counsellor are notified
immediately using a purpose-built study portal. School
counsellors will then follow-up with students within
48 h to offer immediate support, or refer on when ne-
cessary, which is recorded in the portal. The research
team will monitor this portal and directly contact any
counsellors who have not indicated follow-up with
students. If students have changed or left schools, par-
ents will be notified. At the 48-month assessment
point, when students are in their final year of school,
they will also be asked about history of sexual abuse. If
students indicate an experience of sexual abuse, this
same process of notifying the school counsellor will be
followed, and schools will assume the duty of care for
mandatory reporting requirements. This information
will be communicated to relevant university and
school ethics committees, as well as the DSMC follow-
ing each assessment point.
Data collection and management
All research data collected in this trial will be stored
using a unique participant ID code. A list of identifiable
participant information associated with each ID code
will be stored separately from the research data. The
privacy, security and ownership of the research data will
be maintained, and re-identifiable data will not be stored
or accessible by another organisation. Access, storage
and transmission logs will be recorded and regularly
reviewed for anomalies. Annual audits will be conducted
by the trial data manager to ensure compliance with data
security processes outlined by UNSW and Black Dog
Institute.
The data that will be collected include questionnaire
data, mobile phone data and linked data. Coded ques-
tionnaire outcome data will be stored securely on the
Black Dog Institute online research platform until ready
for export. The research platform is stored on UNSW
servers and supported by enterprise access controls and
256-bit encryption or higher. Data will be exported from
the research platform into Microsoft Excel following as-
sessments so that they can be checked by the data man-
ager for data quality and accuracy. After checking, data
will be exported into appropriate statistical software for
analysis. Data collected by mobile phone apps will be
encrypted and transmitted to a secure database hosted
by Google Cloud Services in Australia. Data will be se-
curely removed and transferred on a scheduled basis to
UNSW servers by the trial data manager. Access to Goo-
gle Cloud Services and the UNSW server will require
authentication and will be restricted to the data manager
and named members of the research team. The data
manager will be responsible for extracting and securely
transferring data to the research team. Only researchers
whose analyses require access to the specific dataset col-
lected from each questionnaire, app and linkage data
source will be able to access those data. Linked datasets
will be subject to the requirements set out by linking




Analysis of the primary outcome will be undertaken using
an intention-to-treat approach including all participants
randomised regardless of intervention received, controlling
for baseline differences when appropriate. The primary ana-
lysis will be conducted using planned contrasts comparing
a change in depression scores on the PHQ-A from baseline
to 12 months between the trial arms (SPARX intervention
vs. control), using a mixed-effects model repeated-measure
analysis (MMRM). MMRM is preferred due to the ability
of this approach to include participants with missing data
without using discredited techniques such as last observa-
tion carried forward [87, 88]. School will be included as a
random effect to evaluate and accommodate clustering ef-
fects. Variables used in determining allocation balance will
be evaluated and retained in analyses where they are signifi-
cant or quasi-significant. An unconstrained variance–co-
variance matrix will model within-individual dependencies.
Transformation of scores, including categorisation, may be
undertaken to meet distributional assumptions and accom-
modate outliers.
Secondary and additional outcomes
Secondary and additional outcome analyses will involve
contrasts comparing change on secondary (DQ-5, SCAS,
ISI), and other (e.g., SIDAS) outcomes from baseline to
other occasions of measurement, using an MMRM ap-
proach, as already described.
Additional analyses
Subsidiary complier analyses will be undertaken to com-
pare individuals who complete the intervention relative
to those who do not, in both trial stages. Regression
models will be used to examine risk factors for symp-
toms of psychopathology across the study measurement
points in the control arm. Mediation analyses will be ex-
plored using structural equation modelling. Machine
learning approaches will be used to link multiple data
types with outcomes to discover novel factors which pre-
dict outcomes in terms of specific disorders and their
progression as well as investigate individual patterns of
data that predict individual mental state or symptom
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trajectory. Cost-effectiveness analyses will be conducted
at the primary endpoint and the final measurement
point. Data will be linked to existing records, and educa-
tion and health outcomes will be reported.
Interim analyses
The percentage of participants meeting PHQ-A depres-
sion caseness, scores and reporting of suicidality at each
assessment within both groups will be measured and
reviewed by the DSMC in order to monitor relative
levels of deterioration (accounting for baseline levels),
for safety purposes.
Ethics and dissemination
This study has ethical approval from the University of
New South Wales Human Research Ethics Committee
(HC180836) and NSW Government State Education Re-
search Applications Process Approval (SERAP 2019201),
and has applied for approval from Catholic dioceses and
the Tasmanian Department of Education. The trial is
subject to annual progress reviews with these ethics bod-
ies. The trial is registered with the Australian New Zea-
land Clinical Trials Registry
(ANZCTRN12619000855123). All protocol amendments
will be subject to approval by relevant ethics committees
and listed on the ANZCTR registry. All trial findings will
be presented in aggregate format so that no individual-
level data will be presented.
Public access to the full protocol can be granted from
the authors on reasonable request. Access to
participant-level dataset will be subject to governance
processes set up around a data repository which will
contain data from this study. This will be open for re-
searchers to apply for access.
Trial findings will be communicated using lay lan-
guage and will be made available to participating schools
for publication in school newsletters and/or school web-
sites. Participants and parents will also be provided with
these findings via email. Regular trial progress updates
will be provided by the research team to schools for dis-
tribution through the school community, at their discre-
tion. These findings will also be provided to other
stakeholders in the wider community, including to the
government in policy documents, school counsellor bod-
ies, teacher groups and mental health groups. All find-
ings will be provided at aggregate level. The results of
the trial will be disseminated via peer-reviewed publica-
tions in scientific journals and conferences. No restric-
tions have been imposed on the dissemination of
information by funders.
Discussion
The prevention of depression is critical if the burden of
disease is to be reduced. This study will be the first to
examine the prevention of depression in young people at
scale, using easy-to-access, convenient and private mobile-
phone applications. Efficacy of depression prevention has
been established [17, 19]. What The Future Proofing
Study provides is a large definitive trial investigating the
impact of delivering evidence-based prevention pro-
grammes like CBT at scale, in real-world settings. A large-
scale trial such as this can provide insight into scaling and
implementation processes, which can form the basis of an
ongoing delivery and dissemination framework. The
current study meets this need by examining a depression-
prevention programme, delivered by mobile phone appli-
cations, with access facilitated in the school environment
that is where young people spend most of their time. This
means that, if successful, schools could become the setting
in which access to these programmes is rolled out con-
tinually, future proofing and inoculating all young people
who go through the school system against mental illness.
There are several other features of this trial that
make it novel. The use of a two-staged design, such
that those who show symptoms of depression at the
primary endpoint are randomised to receive a second
intervention targeting insomnia, is innovative. This
second intervention offers an alternative way to reduce
risk for depression onset. The use of smartphone apps
as the primary intervention delivery mechanism is new
in this area [27, 89] and promises reduced costs and
access barriers compared to traditional face-to-face
and health professional-led programmes. The inclu-
sion of smartphone-collected objective data adds an-
other dimension to the trial, allowing for machine
learning approaches to explore whether activity and
location data are associated with, or predictive of,
changes in depression and other mental health symp-
toms. Moreover, linking this rich dataset to govern-
ment education and health records will permit direct
inferences to be made about the impact of mental ill-
ness on health and academic outcomes. Finally, the
continuation of follow-up assessments for 5 years
means that the long-term effects of the interventions
on depression, anxiety, distress, insomnia and add-
itional outcomes can be assessed. The results of The
Future Proofing Study stand to provide a major contri-
bution to the field of digital mental health prevention
programmes, and knowledge about the population-
level impact of preventing depression using these
methods.
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